have developed advanced methods for calculation of the benefit accruing from treatment, with new formulas for the "chance of unqualified success" of a treatment. The primary formula is (p1Ϫp2)[1Ϫ(q1Ϫq2)], where the primary end-point rates in the control and treatment groups are p1 and p2, respectively, and the adverse event rates q2 and q1, respectively. We suggest this formula cannot represent a probability calculation. Consider a hypothetical situation in which treatment reduces end points from 0.9 to 0.1 while reducing the rate of the adverse events from 0.6 to 0.2. The "chance of unqualified success" is 0.8ϫ1.4ϭ1.12, exceeding 1. Other legitimate p and q probabilities between 0 and 1 produce results ranging from Ϫ2 to ϩ2. This contrasts with the allowable range of 0 to 1 for orthodox measures of probability. The formula can therefore be doubted, even when it returns values between 0 and 1.
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Kessler argues that as the NNT US is generally larger than the NNT, more adverse events can be expected in the NNT US group. This is tautologically true but does not alter the meaning of the NNT US concept. 1,2 The NNT US estimates the expected number of individuals who need to be treated to achieve an unqualified success in 1 individual. We do not understand Kessler's claim that the NNH UF does not "compensate for the adverse events that occur in the proportion of the population who cannot benefit from treatment." The NNH UF is calculated from this proportion. If one knew a priori which patients would be "harmed never having had the possibility of benefit," it would be unethical to enroll them into a clinical trial. Kessler's assertion that the majority of adverse events will emanate from patients who will fail to benefit from the treatment implies a dependence between treatment benefit and treatment-induced adverse events. We have dealt with this situation separately. 1(pp378,382 ) The claim that interpretation is confounded when the primary event and the adverse event are not comparable was addressed by the use of utility functions. 1(378 -379),2 "Comparability" was established by determining dollar costs of the desired and untoward effects of therapy.
Francis and colleagues assert that our primary formula, (p1Ϫp2)ϫ (1Ϫ[q1Ϫq2] ), "cannot represent a probability calculation." They should note the mathematical constraints specified in the derivation of this formula: p1Ͼp2 and q1Ͼq2. 1,2 Under these constraints, the formula calculates the product of 2 probabilities. These constraints reflect the common scenario of a treatment that reduces the primary event rate while increasing certain adverse events. But other situations may occur: (1) a poor treatment may increase the primary event rate, and (2) an exceptional treatment may reduce both the primary and adverse event rates. In case 1, the success rate of "control" over treatment can be calculated by reversing the roles of the 2 arms of the study. We applied this to data from the Cardiac Arrhythmia Suppression Trial. 3 In case 2, the rate of treatment-induced adverse events relative to control may in an extreme case be reduced to zero, and an "unqualified success" becomes synonymous with "treatment success," with rate estimated by (p1Ϫp2)ϫ1. The writers claim that the difference of 2 probabilities represents a probability only "when the events of 1 probability are a subset of those in the other" and that "this can never be the case when 2 arms of a trial are being compared." Thus, it is quite impossible to apply this idealized notion to the evaluation of treatment efficacy in a randomized clinical trial. Their example of an extreme gender-by-treatment interaction actually fits into case 1, and calculations can still be carried out as previously outlined. Finally, while the combined end-point rates may have merit in some contexts, our goal was to further develop the NNT concept, which is more clinically useful.
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